Avioq

Executive Summary

Avioq is a privately-held in-vitro diagnostic (IVD) company and contract development and manufacturing organization (CDMO) based in Research Triangle Park, North Carolina. Founded in 2005, the company operates an FDA-licensed and ISO 13485 certified facility focused on infectious disease diagnostics, particularly HIV and HTLV. Avioq provides end-to-end CDMO services, from assay development to commercial production, enabling clients to bring their IVD products to market efficiently. The company's approved stage status suggests it has at least one commercial product or regulatory clearance, positioning it as a reliable partner in the diagnostics space. Avioq's business model leverages its regulatory infrastructure and manufacturing capabilities to serve a growing demand for infectious disease testing. While financial details are not disclosed, the company's specialization in HIV/HTLV aligns with global health priorities, including blood screening and epidemiological surveillance. Key growth drivers include expanding CDMO contracts, increasing adoption of its proprietary tests, and potential geographic expansion. However, as a private entity, Avioq's transparency is limited, and its valuation remains unknown. The company's moderate conviction score reflects its established regulatory approvals but also the lack of recent public milestones or financial data.

Upcoming Catalysts (preview)

• Q2 2026New CDMO contract win with a major diagnostics partner70% success
• Q4 2026FDA clearance for next-generation HTLV assay50% success
• TBDStrategic partnership or acquisition by a larger diagnostics firm30% success